A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function

Abstract

Background/AimsMetronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).MethodsA total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.ResultsThe median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008).ConclusionsMET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.

Transcatheter hepatic arterial infusion chemotherapy vs sorafenib in the treatment of patients with hepatocellular carcinoma of Barcelona Clinic Liver Cancer stage C: a meta-analysis of Asian population

“…On the basis of the inclusion and exclusion criteria of this study, 10 retrospective cohort studies comparing the clinical efficacy and adverse events of HAIC with those of sorafenib for the treatment of BCLC stage C HCCs were finally included. 8 – 17 The flowchart of the search strategy for included studies is shown in Figure 1 . A total of 1,264 patients were included in the study, of whom 505 patients underwent sorafenib treatment and 759 patients underwent HAIC treatment.…”

“…Several studies have reported the clinical effectiveness of HAIC for BCLC stage C HCCs, with response rates ranging from 20.8% to 52%, and the median survival time in complete and partial responders is approximately 40 and 17 months, respectively. 8 – 10 Some previous studies comparing the clinical efficacy of HAIC with that of sorafenib suggested that HAIC was superior to sorafenib for patients with BCLC stage C HCCs. 8 , 12 – 14 However, some other studies reported conflicting results.…”

“… 8 – 10 Some previous studies comparing the clinical efficacy of HAIC with that of sorafenib suggested that HAIC was superior to sorafenib for patients with BCLC stage C HCCs. 8 , 12 – 14 However, some other studies reported conflicting results. 10 , 11 , 15 …”

Selective embolization with magnetized microbeads using magnetic resonance navigation in a controlled‐flow liver model

“…We wrote down the torques s i applied by the external forces (magnetic and gravitational) and by the drag force on the aggregate in Eqs. (6) and (7) and the moment of inertia I in Eq. (8):…”

Liver‑targeted delivery of liposome‑encapsulated curcumol using galactosylated‑stearate

“…The current clinical treatments for liver cancer include surgery, radiotherapy and chemotherapy (1). For patients who miss the optimal timing required for surgery, chemotherapy is the recommended therapy (2). Although the majority of chemotherapy drugs inhibit the excessive proliferation of liver cancer cells, the side effects are may be severe (3)(4)(5).…”